title: Evaluation of a standardized short-time calcium suppression test in healthy subjects: interest for the diagnosis of primary hyperparathyroidism.
abstract: OBJECTIVE
  The diagnosis of primary hyperparathyroidism (PHP) can be difficult in patients with normal plasma calcium or parathyroid hormone (PTH) levels. We perfected a standardized short-time i.v. calcium loading test in healthy controls (HC) and compared the results with those of patients with PHP.
  
  
  METHODS
  Sixteen HC received 0.33 mmol/kg calcium gluconate intravenously for 3 h. Plasma calcium and serum PTH levels (assayed with immunoluminescent sandwich methods) were measured before, at the end of the infusion and 3 h later. Results were compared with those of 16 PHP patients.
  
  
  RESULTS
  In HC, basal total plasma calcium (mean +/- s.e.m.) was 2.33 +/- 0.02 mmol/l. At the end of calcium loading, calcemia reached 3.21 +/- 0.05 mmol/l and decreased to 2.94 +/- 0.08 mmol/l 3 h later. In PHP patients, basal plasma calcium was 2.54 +/- 0.03 mmol/l and reached similar values as in HC during the testing. Basal serum PTH levels were 32.5 +/- 3.3 ng/l in HC and 86.9 +/- 6.3 ng/l in PHP. At the end of calcium loading, they dropped to 8.8 +/- 0.6 ng/l (HC) and to 31.4 +/- 4.2 ng/l (PHP). Three hours later, they were 11.6 +/- 0.8 and 39.8 +/- 4.0 ng/l respectively. There was a cut-off in serum PTH values between the two groups at the end of calcium loading and 3 h later.
  
  
  CONCLUSIONS
  The standardized short-time PTH suppression test appears reliable to differentiate healthy subjects from PHP whose serum PTH levels remain >14 and >23 ng/ml respectively at the end of loading and 3 h later. This well-tolerated and easily performed test could be used for the diagnosis of PHP in patients suspected for the disease despite the normality of some basal biological markers.
authors.affiliation: Department of Endocrinology, Clinical Research Center INSERM 0204, Rouen University Hospital, Rouen, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Titon
authors.forename: Anne
authors.initials: A
authors.lastname: Cailleux-Bounacer
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Basuyau
authors.forename: Hervé
authors.initials: H
authors.lastname: Lefebvre
authors.forename: Adeline
authors.initials: A
authors.lastname: Savouré
authors.forename: Jean Marc
authors.initials: JM
authors.lastname: Kuhn
mesh_terms: D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood*; D002125:Calcium Gluconate / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000097:blood* / Q000175:diagnosis*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D015203:Reproducibility of Results; D012709:Serum Albumin
chemical_list: D010281:Parathyroid Hormone; D012709:Serum Albumin; D010758:Phosphorus; D002125:Calcium Gluconate; D002118:Calcium